Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System
Phase of Trial: Phase IV
Latest Information Update: 26 Jan 2018
At a glance
- Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Jan 2018 Results assessing stroke and major bleeding risks presented at the International Stroke Conference 2018
- 25 Jan 2018 According to a Boehringer Ingelheim Pharmaceuticals media release, results were presented at the International Stroke Conference 2018.
- 25 Jan 2018 Results presented in a Boehringer Ingelheim Pharmaceuticals Media Release.